Merck agrees to acquire Bio-Techne for $11.3 billion to expand life sciences and multiomics capabilities (bioanalysis-zone.com)

• Merck to acquire Bio-Techne for $11.3bn, its largest deal in over a decade.
• Bio-Techne's multiomics, spatial biology, and protein analysis platforms will complement Merck's life sciences portfolio.
• The acquisition targets drug discovery, precision diagnostics, and cell and gene therapy markets.

"Merck (Darmstadt, Germany) has agreed to acquire US-based Bio-Techne for $11.3 billion, its largest deal in over a decade. The acquisition will add Bio-Techne's multiomics, spatial biology, protein analysis, and RNAscope platforms to Merck's portfolio, targeting drug discovery, diagnostics, and advanced therapeutics. The deal reflects growing demand for integrated multiomics and analytical tools in biopharma R&D."